Hyperprolactinemic infertile women. Female infertility associated with anovulation
Conditions
Interventions
Intervention 1: Bromocriptine 2.5 mg BID. Intervention 2: Cabergoline 0.25 mg twice a week.
Treatment - Drugs
Bromocriptine 2.5 mg BID
Sponsors
Research deputy of Shiraz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
19 Years to 38 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1) Primary or secondary infertility, 2) Hyperprolactinemia with or without galactorrhea (prolactin>20ng/ml), 3) Normal HA except high prolactin level, normal HSG or laparoscopy and normal SA. Exclusion criteria: 1) other causes of infertility such as tubal factor, male factor or unexplained infertility, 2) nausea, vomiting, orthostatic hypotension, chronic hypertension, headache, 3) sensitivity to ergot derivatives, 4) macroadenoma of pituitary gland, 5) previous use of bromocriptine or cabergoline
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The occurrence of pregnancy. Timepoint: At 6-7 weeks of gestational age. Method of measurement: Transvaginal sonography. | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment side effects. Timepoint: Every 4 weeks. Method of measurement: Check list.;Serum prolactin level. Timepoint: 4 weeks after treatment. Method of measurement: Laboratory measurment. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyed-Mohammad Fereshtehnejad
Iran University of Medical Sciences and Health Services
Outcome results
None listed